Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 383 publications.

Handels R, Herring WL, Grimm S, Skoldunger A, Winblad B, Wimo A, Jonsson L. New IPECAD open-source model framework for the health technology assessment of early Alzheimer's disease treatment: development and use cases. Value Health. 2025 Apr;28(4):511-8. doi: 10.1016/j.jval.2024.07.009

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease. Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006

Vickers AD. A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis. Value Health. 2025 Apr;28(4):591-8. doi: 10.1016/j.jval.2025.01.005

Marcano Belisario J, Lunan M, Hawe E, Thurairajah S. Machine learning and artificial intelligence for supporting systematic reviews: a systematic review of recent methodological developments and recommendations for implementation. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S636. doi: 10.1016/j.jval.2024.10.3193

Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619

Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Sullivan SD. Economic evaluation of dupilumab versus standard of care for the treatment of adult patients with moderate-to-severe prurigo nodularis in the United States. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S104. doi: 10.1016/j.jval.2024.10.543

Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Johannesen K, Herring WL, Chopra R, Elpers B, Dong O. Using patient-level simulation to estimate long-term survival in idiopathic pulmonary fibrosis. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S459-60. doi: 10.1016/j.jval.2024.10.2345

Burgess B, Leng X, Brizan J, Hawe E. Meta-analysis of pre-post studies: why standardised mean difference should be avoided. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S439. doi: 10.1016/j.jval.2024.10.2243

Clemmet T, Campbell K, Basarir H. Key features of economic models used in submissions to NICE in dermatology indications. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):s155. doi: 10.1016/j.jval.2024.10.784

Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.620

Desai A, Dong OM, Gautier S, Johnson T, Wong A, Osman AMY, Harvey J, Tran TH, Holladay Ford DM, Kerr KW, Aggarwal A, Mauskopf J. A systematic review of health economic evaluations of oral nutritional supplements as a single-component or multi-component intervention in older adults with or at risk of malnutrition. Poster presented at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12):S120.

Ronquest N, Zhang Y, Paret K, Armstrong S, Mostovoy L, Berggren R. Identifying the value drivers in obesity treatment: a targeted review of weight loss effects on health economic outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S148. doi: 10.1016/j.jval.2024.10.752

Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S43. doi: 10.1016/j.jval.2024.10.228

Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K. Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S77. doi: 10.1016/j.jval.2024.03.405

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735

Dong OM, Herring W, Chopra P, Elpers B, Johannesen K. A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S148. doi: 10.1016/j.jval.2024.03.2259

Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236

Graham CN, Erbe AW. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Yande S, Johnson ML, Aparasu RR, Toale K, Wanat M. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins in cancer associated thrombosis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S179. doi: 10.1016/j.jval.2024.03.969

Korgaonkar S, Bentley J, Holmes E, Barnard M, Ramachandran S, Chang Y, Yang Y. Measurement of health insurance literacy and identification of its correlates among working-age cancer survivors in the US. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S345. doi: 10.1016/j.jval.2024.03.2143

O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580

Miles L, Mauskopf J. Enhancing the value and usefulness of data extracted from an economic systematic literature review. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S407. doi: 10.1016/j.jval.2024.03.1916

Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772

Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189

Houghton K, Nangia A, Hawe E. Use of external control arms (ECAs) in marketing applications submitted to European medicines agency (EMA): a targeted review. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S404. doi: 10.1016/j.jval.2023.09.2119

Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488]. Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010

Nangia A, Houghton K, Hawe E. Use of external control arms in pharmaceutical submissions to the national institute for health and care excellence for technology appraisals: a targeted review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S416. doi: 10.1016/j.jval.2023.09.2180

Cook C, Carrico J, Talbird S, Sabale U, Dolk C, Bencina G. Public health impact of the pediatric immunization program in the Netherlands. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S135-6. doi: 10.1016/j.jval.2023.09.705

Hawe E, Simou E, Balp MM, Kohli R, Wiyani A. Influence of disease activity and angioedema on EQ-5D-5L utility scores in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S500. doi: 10.1016/j.jval.2023.09.2697

Handels R, Herring W, Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I. IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S419. doi: 10.1016/j.jval.2023.09.2194

Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML. Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S286. doi: 10.1016/j.jval.2023.09.1502

Vickers A, Leng X. The impact of life expectancy exclusion criteria on survival curve extrapolation. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S406. doi: 10.1016/j.jval.2023.09.2131

Vickers A. The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S400-1. doi: 10.1016/j.jval.2023.09.2098

Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271

Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493

Jen MH, Kiiskinen U, Khanal M, Han Y, Hess L, Tian W, Vickers A. Matching Adjusted Indirect Comparison (MAIC) of selpercatinib Vs cabozantinib in RET mutation-positive advanced Medullary Thyroid Cancer (MTC). Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S18. doi: 10.1016/j.jval.2023.09.094

Cadarette S, Rementeria MA, Espinosa EG, Stewart F, Brisibe T, Devani D, Kistler K, Oladapo T, Rangi ND, Wissinger E. Quality of life (QOL) instruments used in clinicaltrials.gov-indexed trials of gene-modified cell therapy (GMCT) in patients with multiple myeloma (MM). Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S495. doi: 10.1016/j.jval.2023.09.2676

Erbe AW, Kendzia D, Busink E, Carroll S, Aas E. Value of an integrated home dialysis model in the United Kingdom: a cost-effectiveness analysis. Value Health. 2023 Jul;26(7):984-94. doi: 10.1016/j.jval.2023.02.009

Aris E, Brabant Y, La E, Candrilli S, Molnar D. Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S124. doi: 10.1016/j.jval.2023.03.657

Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA. A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S45. doi: 10.1016/j.jval.2023.03.2298

Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405

Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S115-6. doi: 10.1016/j.jval.2023.03.611

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S187. doi: 10.1016/j.jval.2023.03.1013

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927

Houghton K, Hitchens A, Ciepielewska M. Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S155. doi: 10.1016/j.jval.2023.03.2501

Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S180. doi: 10.1016/j.jval.2023.03.972

Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S66-7. doi: 10.1016/j.jval.2023.03.347